CCL21 And Checkpoint Inhibitors For The Treatment Of Cancer
Tech ID: 29788 / UC Case 2018-912-0
Researchers at the UCLA David Geffen School of Medicine have demonstrated a combination therapy of intratumoral administration of
CCL21-gene modified human monocyte-derived dendritic cells and intravenous
administration of anti-PD-1 inhibitor enhances tumor CD8+ T cell infiltration
and reduces tumor growth.
inhibitors, such as anti-programmed death-1 receptor/programmed death-ligand 1
(anti-PD-1/PD-L1) elicit promising antitumor responses in the treatment of a
broad spectrum of cancers, through modulation of immune cell-tumor cell
interaction. However, the majority of the patients exhibit poor clinical
responses to PD-1/PD-L1 inhibitor treatment due to primary, adaptive, or
acquired resistance to the treatment. Thus, an effective cancer immunotherapy requires
methods to restore deficits in tumor antigen presentation and functional
antitumor effector activities.
CCL21 is a secondary lymphoid
chemokine that, upon binding to the CCR7 gene receptor, functions as a
chemo-attractant for mature dendritic, naïve, and memory T cells, enhancing
cell-mediated immunity against tumor cells. Intratumoral administration of
CCL21 gene-modified dendritic cells (AdCCL21-DC) leads to increases of CD4+,
CD8+, and CD11c+DEC205+ DCs infiltration of the tumor, decrease of immune-suppressive
molecules in the tumor microenvironment, as well as reduction of tumor burden
in murine lung cancer model. More importantly, intratumoral administration of
AdCCL21-DC also enhances CD8+ T cell infiltration and increased tumor PD-L1
expression in advanced non-small cell lung cancer (NSCLC) patients.
Researchers at UCLA have shown
that advanced NSCLC patients with baseline PD-L1 expression benefit the most
from anti-PD-1 treatment, suggesting responses to PD-1/PD-L1 blockade are more
likely in the setting of tumor PD-L1 expression and a pre-existing T lymphocyte
infiltration of the tumor. Indeed, these researchers have shown that AdCCL21-DC
and anti-PD-1 combination therapy outperforms both mono-therapies in syngeneic murine
lung cancer models. Specifically, the combination therapy significantly
enhances the cytolytic activity of tumor-infiltrating lymphocytes (TILs)
against tumor, accompanied by significant reduction in tumor volume and tumor
NSCLC, melanoma and other types of solid tumors.
- Improve clinical
response to anti-PD-1/PD-L1 therapy
- Boosts local and
systemic immune responses
- Reduce tumor
burden and tumor growth
State Of Development
Completed pre-clinical studies in murine lung cancer models and phase I trials. The combination trial
with anti-PD1 is starting now.
|Patent Cooperation Treaty
Additional Patent Pending
- Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM, Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration. Clin. Cancer Res., 2017.
- Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S, CCL21 Chemokine Therapy for Lung Cancer, Int. Trends Immun., 2013.
- Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, Dubinett SM, Rome LH, Sharma S, Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth, PLoS One, 2011.
- Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM, Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer, J. Transl. Med., 2008.
- Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM, Sharma S, CCL19 reduces tumour burden in a model of advanced lung cancer, Br. J. Cancer, 2006.
- Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S, Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma, Cancer Res., 2006.
- Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S, Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity, Clin. Cancer Res., 2004.
- Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S, Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells, Mol. Cancer, 2003.
- Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM, SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10, Mol. Cancer, 2003.
- Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R, Dubinett SM, Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma, Cancer Res., 2001.
- Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM, Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo, J. Immunol., 2000.